[Evaluation of the hemodynamic effects of the long-acting peripheral vasodilator flosequinan in patients with chronic heart failure].
The hemodynamic effects of the peripheral vasodilator flosequinan, 100 mg/day, were evaluated in 20 patients with Stage IIA-IIB (the Lang-Strazhesko-Vasilenko classification) heart failure. The doses of digoxin and diuretics were found to be stable. The right cardiac cavities and pulmonary artery were catheterized by Swan-Ganz balloon catheters. The agent was demonstrated to produced profound effects showing decreased pre- and afterload when given both in a single dose or in course therapy.
Abdurakhmanov
U S
US
Naumov
V G
VG
Shevliagin
S A
SA
Novikov
S V
SV
Mareev
V Iu
VIu
Belenkov
Iu N
IuN
D000328:Adult; D002908:Chronic Disease; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
D011804:Quinolines; D014665:Vasodilator Agents; C047316:flosequinan
Otsenka gemodinamicheskogo deĭstviia prolongirovannogo perifericheskogo vazodilatatora flozekvinana u bol'nykh s khronicheskoĭ serdechnoĭ nedostatochnost'iu.